Ricerca adds to DMPK team

William DeMaio joins from Wyeth Research

Ricerca, a US-based preclinical contract research organisation (CRO) providing services to the biopharmaceutical industry, has added William DeMaio, as senior director of its drug metabolism and pharmacokinetics (DMPK) department.

DeMaio joins a team of bioanalytical and drug metabolism scientists that provides integrated pharmaceutical development services and analytical problem solving capabilities, offering support for Ricerca’s discovery and preclinical development programmes.

Prior to joining Ricerca, DeMaio was associate director of biotransformation at Wyeth Research (now Pfizer) in Collegeville, Pennsylvania, where he was responsible for drug metabolite identification and metabolism characterisation by mass spectrometry. He has expertise in chromatography, mass spectrometry, structural elucidation and drug development, as well as operating GLP-compliant bioanalytical and metabolism operations and training analysts in use of LC/MS equipment and data analysis.

You may also like

Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Ricerca announces similarity analysis service

Foresight allows compound assay results to be compared against pharmacologically active compounds
Research & Development

Ricerca and LSP agree business development collaboration

Ricerca will expand its presence in Japan, Korea and overall Asian market
Regulatory

Ricerca completes purchase of MDS Pharma businesses

The acquisition gives Ohio-based Ricerca more capacity and capabilities.
Research & Development

MDS to sell early stage business to Ricerca

MDS Pharma Services is to sell its remaining discovery and pre-clinical operations to Ohio-based Ricerca Biosciences for US$45m.
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

The path to commercial allogeneic iPSC therapies

The cell therapy sector is currently shifting from patient-specific autologous treatments toward off-the-shelf allogeneic cell therapies. Although this transition is helping to democratise access to treatments, it introduces several challenges in terms of controlling complex biology at a commercial scale
Research & Development

The IND advantage: why early derisking is a strategic imperative for complex biologics

As biologics grow more complex, early identification and the mitigation of manufacturability, stability and immunogenicity risks have become the critical factor separating programmes that reach IND on time from those that don't, says Yvette Stallwood, Head of Early Development Services at Lonza
Subscribe now